Newsletter | May 12, 2022

05.12.22 -- Expanding RNA-Based Immune Profiling

 
Virtual Event
Featured Editorial
Industry Insights
Cell Culture Media Dipeptides For Biopharma Process Improvement

With the right selection of dipeptides, keto acids, special amino acids, or other derivatives at hand, biopharma companies can realize substantial process improvements.

Mitigate Risk By Being Courier Agnostic

Shipping critical, high-value, temperature-sensitive materials is among the many challenges of COVID-19. One of the fundamental ways to mitigate risk is by not being tied to any courier.

Keys To Successful Risk Management In Clinical Trials

Effective risk management recognizes variables unique to each clinical trial while embracing consistent documentation practices, stakeholder responsibility, and best practices informed by experience.

Robotics, Isolators, And Restricted Access Barrier Systems (RABS)

The aim of advanced aseptic processing is the elimination and absolute control of all sources of contamination – most importantly, human generated contamination. Robotics and isolator barrier systems are core technologies in this endeavor.

The Promise Of Cell And Gene Therapies For Rare Diseases

We explore the challenges of developing cell and gene therapies and the innovations in biotechnology that may help offer more solutions, which will soon be available to patients who have little else to turn to.

Single-Use Solutions For Research And Process Development

Can supply chain assurance be maintained while offering an array of possibilities to achieve complex process designs? Learn if your organization could benefit from a modularized and standardized single-use manifold design.

A Platform Standard For Viral Vector Manufacturing And Commercialization

Learn more about platform technologies that are being developed and implemented to support large-scale production of viral vectors.

Quantifying Quality Attributes Of AAV Gene Therapy Vectors By SEC-UV-MALS-dRI

In this application note, we present a simple, robust, and direct SEC method with UV-MALS-dRI detection that allows rapid sample analysis and can be readily employed to quantify AAV particle concentration, capsid content, and aggregation throughout the AAV product development and manufacturing processes.

Fluoropolymer Material Advantages In Biomanufacturing

In this poster we review how the Aramus Fluoropolymer Bag performs in various temperatures, the frozen drop performance, and chemical compatibility.

Insights On Cell And Gene Therapy Manufacturing

Since the early 1990s, gene therapy has revolutionized medicine. In the coming years, it will continue to become more relevant in the treatment and cure of some of the most severe diseases and disorders.

The Canadian Regulatory System For Cell And Gene Therapies

Review how cell and gene therapy products are regulated in Canada, the regulatory framework and environment, and how to navigate the Canadian regulatory system.

Radiance Label-Free Monitoring Of AAV Transfection In HEK293 Cells

LumaCyte’s Radiance® instrument has the potential to improve the characterization of cell-based AAV transfection and production, improving the efficiency and accuracy of both processes and shortening development time.

Solving Logistic Complexities In The Era Of Personalized Medicine

Examine how the next generation of therapies is disrupting supply chain logistics and explore solutions for the complexities within cell and gene therapies.

Regulatory And Cost Implications For Switching Injectable Delivery Formats

Launching a large molecule in one format and then switching the delivery format often transpires as a life cycle management strategy that provides cost-effective solutions, supply chain continuity, and patient benefits. 

Large-Scale AAV Manufacturing: The Road From Concept To Ready-To-Use Platform

Review the critical parameters for scalable production during upstream and downstream process development, with details on achieving scalable transfection in adherent and suspension platforms.

Strategies For Scaling Up mRNA Manufacturing

The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.

Sponsor
Solutions
Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.